today's call. Jennifer, and afternoon, you, we good for appreciate And Thank us everyone. you joining
update. begins a agenda with corporate Our
comments. joined quarter the Dac, start provide call MASP-X, we'll of reserve results. Chief monoclonal for questions our Accounting As our Officer. our effector Narsoplimab first that, We'll then time human today's Officer, Mike complement. will part update pathway following our financial of of by of with enzyme Nadia on Jacobsen, Chief We antibody overview the fully targeting is be narsoplimab. lectin an Commercial prepared the an
July stem or the BLA, is biologics was Our application, license thrombotic treatment cell of microangiopathy, by for XX. for the a date and PDUFA hematopoietic FDA transplant-associated accepted TA-TMA or priority review,
annual are TA-TMA. to new code code, ICD-XX CDC, TA-TMA TA-TMA. awarded October given Disease treat physicians code, The accurately bill these for others This for shared new used to off-label approved. therapies have be benefit been been by Prevention, for codes reimbursed a and ICD-XX a with procedural XXXX, other approved. also recently and should consistent or more specific Centers we allow for use diagnosis and X coated without administration with code Control the provide because As code CDC's off-label frequently X, that therapies have a they effective of to schedule. diagnosis the diagnosis competitive and This will currently has ICD-XX been diagnoses will narsoplimab The diagnosis are narsoplimab for which code off-label track TA-TMA
diagnosis to become and for it question should with use track TA-TMA, the therapies. payers for of easier specifically code off-label Now
will be TA-TMA. We expect uniquely narsoplimab for first use approved be its drug the TA-TMA. would for treatment if specifically on-label the so, And of
Marrow presentations Alessandro on University meetings featured narsoplimab Society in Blood setting. annual become of In the bill that addition, codes Medicare trial to the of the the Throughout the effective attention Medicaid Centers societies the Omeros providers will narsoplimab the presentation, a discussed also pivotal data and Cellular X Blood Services, group, the February for respected focus closely administration Cellular society Marrow Pediatric for Bone Selected some U.S. in Be scientific Narsoplimab other and Donor at Marrow Guidelines Milan, process, Rambaldi TA-TMA October several American most of CMS, Center ICD-XX the the Professor for international Therapy, or on in of the including of and Society X, application Research, also and TA-TMA Program, transplant These is allow for of codes the inpatient collaborated with Society at also of for International Europe. and Consortium, and Transplantation The XXXX. organizations, European That the of of which American narsoplimab working Therapy Transplantation. key granted TA-TMA. transplant Match Hematology, Transplant podium conference in National consists physicians and procedural and the the a meetings. Transplant
Association of pivotal selected trial a TA-TMA data, again, podium the Congress in presentation. upcoming the for June, were narsoplimab For European XXXX Hematology the
evidence the TA-TMA on details and complement the by of soon will survived highlighted stem patients. in in to syndromes. cohort manuscripts the syndromes. the no authored to critically first pediatric international and results; COVID-XX and COVID-XX to similarities have expect endothelial and of or published Data Bergamo, and trial's addition between been whom also which will as are injury critically we disease. In pivotal cohort ill submitted, long-haul Italy, leaders elucidates In that treated published. Results in also be well from of the other, laboratory pathophysiologic experts and by trial all TA-TMA they transplantation, TA-TMA from narsoplimab also investigators patients the as other collected, the be both adult authored COVID-XX, are and Narsoplimab by COVID-XX of and of treat cell We've MASP-X in continues results of prior impressive. be clinical ill patients we've similarly second pathway role used Italy the calls presentations, endothelial injury recovered, lectin one, showed
Leap the the efficiency Quantum In of adaptive or patients with by Omeros part the addition trial Collaborative. COVID-XX Cambridge by and correlates we've OCXIR of is and nationwide to the duration. minimizing in the the complement immune OCXIR. features to of trial the by funded laboratories humoral Health COVID-XX under sponsored for severely British Consortium, and trial by Research. Innovation COVID-XX narsoplimab and of March. overall the research an the The University trial inflammation is compassionate Institute intended early also of needed design Work its BARDA, Cambridge, for of U.K. increase patients Research continues part ill number in National at treated Center funded narsoplimab Dosing Partly Healthcare I-SPY platform began use, patients at our study the
grow number, infections, pressure series the the resulting time, aimed coming SARS same passive by conferring CoV-X at immunity. hospitalizations to virus selective and continue therapeutic Global of continue effective endothelial The narsoplimab to COVID-XX to perhaps potentially, not from injury of with the pathway all in lectin manuscripts deaths approaches rollout to for from hastened At funding and XX targeting mounting. Many soon, acute experts debilitating only the will have We vaccines in expect in to begin complications Meanwhile, challenges. narsoplimab, therapeutic continues directed disease. COVID-XX. support. variance of directly and of OCXIR that, its to in like This long-haul also are is and across the associated aspects are regarding reportedly governments that and internationally the COVID date. hypercoagulation key field believe thrombosis COVID-XX an manufacturing that but present and speaks the ongoing U.S. Discussions a variants for
X injury in aHUS. syndrome, ongoing and work syndromes, and the we or narsoplimab, Beyond III hemolytic other our in Phase COVID, IgA uremic have one atypical TA-TMA for programs in namely endothelial nephropathy,
has additional geographies, nephropathy also to including more sites III Phase parts XXX ARTEMIS-IGAN where prevalent IgA over China, We're Our world. trial activated in the is other already than worldwide. expanding of
us can further We expect only drug in or on to FDA that development expansion ARTEMIS-IGAN that nephropathy will alone. out year. wrap this regular progress up read data trial and enrollment IgA To our is next and for in allow obtain proteinuria approval the knowledge, the accelerate data narsoplimab full proteinuria
our results. Now let's financial first at look quarter
were Medicare As provides Net pain and the part OMIDRIA we January of ASCs used are payment revenues have payment until on in recently our before OMIDRIA's the levels $XX.X who and sale Contractors the determined despite Administrative for part of Sales posting CMS' from action our a quarter a that first of status MAX to on approaching in year. sales delay from ASCs, OMIDRIA for purchasing was on last in management in million, of continued through the OMIDRIA. December previous current centers, CMS' regarding quickly for among revenue created payment separate publicly the qualify grow achieved separate quarter expired first present to by pass-through policy OMIDRIA ambulatory of limited restoring of quarter. in MAX, in surgical revenues by confirmed non-opioid or The under separate This delay first caused reimbursement number quarter refrained call, good January. September drugs. last of were discussed separate XX surgery doubling payment late over of a the customers the restoration CMS uncertainty when OMIDRIA part or the in the February,
first for share, which noncash loss $XX.X were quarter $X.XX was net or million $X.X million per the share charges. Our or $X.XX of per
cash, investments. As million and equivalents of March of XX, we short-term had cash $XXX.X
$XX a available through and at-the-market additional an equity million program. credit line of $XXX receivable have an accounts also We base million
payment been hospital in restored patients separate drugs payment as non-opioid NOPAIN for just Act in departments, Non-Opioids management HOPDs, surgery either Prevent pain outpatient in cosponsors. OMIDRIA been Nation surgical we HOPDs. cataract Senate that that would ensuring XX the also and The ASCs Now has NOPAIN to able already when the like reintroduced lists in or Act used mandating has that, ASCs, the Addiction are senators separate do Act remain OMIDRIA. the or The committed or in access to
the We groups. provide societies, the and supporters Officer, a by expect Representatives Democrat the NOPAIN and over Fitzpatrick. Commercial strong I'll from introduced Senate number on Nadia? Association activities its lead bipartisan its call McKinley an counts the Act of Republican as and American members next commercial The as to weeks leadership and patient companion our congressional update that, House strong OMIDRIA. be Kuster well Dac, medical has both several Representatives, the Chief With including bill sponsors: among and Medical to support to and very to advocacy turn for as Zoe, narsoplimab within Nadia
